Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 440-449

  Rahnasto, Minna ^a   Raunio, Hannu ^a   Poso, Antti ^a   Wittekindt, Carsten ^a   Juvonen, Risto O ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORONAPHTHALENE; 1 METHYLNAPHTHALENE; 1 NAPHTHOL; 1,2 DICHLORONAPHTHALENE; 1,2 DIMETHYLNAPHTHALENE; 1,2,3,6,7 PENTACHLORONAPHTHALENE; 1,3 DIMETHYLNAPHTHALENE; 1,5 DICHLORONAPHTHALENE; 1,5 DIMETHYLNAPHTHALENE; 1,6 DIMETHYLNAPHTHALENE; 1,7 DIMETHYLNAPHTHALENE; 2 BROMONAPHTHALENE; 2 CHLORONAPHTHALENE; 2 ETHYLNAPHTHALENE; 2 FLUORONAPHTHALENE; 2 METHOXYNAPHTHALENE; 2 METHYLNAPHTHALENE; 2 NAPHTHOL; 2,3 DICHLORONAPHTHALENE; 2,6 DIMETHYLNAPHTHALENE; 2,7 DICHLORONAPHTHALENE; 2,7 DIMETHYLNAPHTHALENE; 7 METHYL 2 NAPHTHALDEHYDE; CYTOCHROME P450 2A5; CYTOCHROME P450 2A6; ENZYME INHIBITOR; NAPHTHALENE; NAPHTHALENE DERIVATIVE; PHENANTHRENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; SMOKING CESSATION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICE; MIXED FUNCTION OXYGENASES; NICOTINE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12344337351     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049536b     Document Type: Article

References (46)

1. Khurana, S.; Batra, V.; Patkar, A. A.; Leone, F. T. Twenty-First Century Tobacco Use: It is not Just a Risk Factor Anymore. Respir. Med. 2003, 97, 295-301.
2. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life; World Health Organization: Geneva, 2002.
3. Ezzati, M.; Vander Hoorn, S.; Rodgers, A.; Lopez, A. D.; Mathers, C. D.; Murray, C. J. L. Estimates of Global and Regional Potential Health Gains from Reducing Multiple Major Risk Factors. Lancet 2003, 362, 271-280.
4. Benowitz, N. L. Pharmacology of Nicotine: Addiction and Therapeutics. Annu. Rev. Pharmacol. Toxicol. 1998, 36, 597-613.
5. Oscarson, M. Genetic Polymorphisms in the Cytochrome P450 2A6 (CYP2A6) Gene: Implications for Interindividual Differences in Nicotine Metabolism. Drug Metab. Dispos. 2001, 29, 91-95.
6. Raunio, H.; Rautio, A.; Gulstenn, H.; Pelkonen, O. Polymorphisms of CYP2A6 and its Practical Consequences. Br. J Clin. Pharmacol. 2001, 52, 357-363.
7. Sellers, E. M.; Tyndale, R. F.; Fernandes, L. C. Decreasing Smoking Behaviour and Risk Through CYP2A6 Inhibition. Drug Discovery Today 2003, 8, 487-493.
8. Kitagawa, K.; Kunugita, N.; Katoh, T.; Yang M.; Kawamoto, T. The Significance of the Homozygous CYP2A6 Deletion on Nicotine Metabolism: a New Genotyping Method of CYP2A6 Using a Single PCR-RFLP. Biochem. Biophys. Res. Commun. 1999, 262, 146-151.
9. Inoue, K.; Yamazaki, H.; Shimada, T. CYP2A6 Genetic Polymorphisms and Liver Microsomal Coumarin and Nicotine Oxidation Activities in Japanese and Caucasians. Arch. Toxicol. 2000, 73, 532-539.
10. Nakajima, M.; Yamagishi, S. I.; Yamamoto, H.; Yamamoto, T.; Kuroiwa, Y.; Yokoi, T. Deficient Cotinine Formation from Nicotine is Attributed to the Whole Deletion of the CYP2A6 Gene in Humans. Clin. Pharmacol. Ther. 2000, 67, 57-69.
11. Tyndale, R. F.; Sellers, E.; M. Genetic Variation in CYP2A6 mediated Nicotine Metabolism Alters Smoking Behavior. Ther. Drug Monit. 2002, 24, 163-171.
12. Sellers, E. M.; Kaplan, H. L.; Tyndale, R. F. Inhibition of Cytochrome P450 2A6 Increases Nicotine's oral Bioavailability and Decreases Smoking. Clin. Pharmacol. Ther. 2000, 68, 35-43.
13. Tyndale, R. F.; Sellers, E. M. Variable CYP2A6 Mediated Nicotine Metabolism Alters Smoking Behavior and Risk. Drug Metab. Dispos. 2001, 29, 548-552.
14. Takeuchi, H.; Saoo, K.; Yokohira, M.; Ikeda, M.; Maeta, H.; Miyazaki M.; Yamazaki H.; Kamataki, T.; Imaida, K. Pretreatment with 8-Methoxypsoralen, a Potent Human CYP2A6 Inhibitor, Strongly Inhibits Lung Tumorigenesis Induced by 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Female A7J Mice. Cancer Res. 2003, 63, 7581-7583.
15. Miyamoto, M.; Umetsu, Y.; Dosaka-Akita, H.; Sawamura, Y.; Yokota, J.; Kunitoh, H.; Nemoto, N.; Sato, K.; Ariyoshi Kamataki, T. CYP2A6 Gene Deletion Reduces Susceptibility to Lung Cancer. Biochem. Biophys. Res. Commun. 1999, 267, 658-660.
16. Juvonen, R. O.; Gynther, J.; Pasanen, M.; Alhava, E.; Poso, A. Pronounced Differences in Inhibition Potency of Lactone and Non-lactone Compounds for Mouse and Human Coumarin 7-Hydroxylases (CYP2A5 and CYP2A6). Xenobiotica 2000, 30, 81-92.
17. Draper, A. J.; Madan, A.; Parkinson, A. Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes. Arch. Biochem. Biophys. 1997, 341, 47-61.
18. Mäenpää, J.; Sigushi, H.; Raunio, H.; Syngelma, T.; Vuorela, P.; Vuorela, H.; Pelkonen, O. Differential Inhibition of Coumarin 7-Hydroxylase Activity in Mouse and Human Liver Microsomes. Biochem. Pharmacol. 1993, 45, 1035-1042.
19. Kimonen, T.; Pasanen, M.; Gynther, J.; Poso, A.; Järvinen, T.; Alhava, E.; Juvonen, R. O. Competitive Inhibition of Coumarin 7-Hydroxylation by Pilocarpine and Its Interaction with Mouse CYP 2A5 and human CYP 2A6. Br. J. Pharmacol. 1995, 116, 2652-2630.
20. Fujita, K.; Kamataki, T. Screening of Organosulfur Compounds as Inhibitors of Human CYP2A6. Drug Metab. Dispos. 2001, 29, 983-989.
21. Poso, A.; Juvonen, R.; Gynther, J. Comparative Molecular Field Analysis of Compounds with CYP2A5 Binding Affinity. Quant. Struct.-Act. Relat. 1995, 14, 507-511.
22. Poso, A.; Gynther, J.; Juvonen, R. A Comparative Molecular Field Analysis of Cytochrome P450 2A5 and 2A6 Inhibitors. J. Comput.-Aided Mol. Des 2001, 15, 195-202.
23. Lewis, D. F.; Dickins, M.; Lake, B. G.; Eddershaw, P. J.; Tarbit, M. H.; Goldfarb, P. S. Molecular Modelling of the Human Cytochrome P450 Isoform CYP2A6 and Investigations of CYP2A Substrate Selectivity. Toxicology 1999, 133, 1-33.
24. Asikainen, A.; Tarhanen, J.; Poso, A.; Pasanen, M.; Alhava, E.; Juvonen, R. O. Predictive Value of Comparative Molecular Field Analysis Modelling of Naphthalene Inhibition of Human CYP2A6 and Mouse CYP2A5 Enzymes. Toxicol. in Vitro 2003, 17, 449-455.
25. Juvonen, R.; Kaipainen, P. K.; Lang, M. A. Selective Induction of Coumarin 7-Hydroxylase by Pyrazole in D2 mice. Eur. J. Biochem. 1985, 152, 3-8.
26. Lang, M. A.; Nebert, D. W. Structural Gene Products of the Ah Locus. Evidence for Many Unique P-450-mediated Monooxygenase Activities Reconstituted from 3-Methylcholanthrene-Treated C57BL/6N Mouse Liver Microsomes. J. Biol. Chem. 1981, 256, 12058-12067.
27. Kimonen, T.; Juvonen, R. O.; Alhava, E.; Pasanen, M. The Inhibition of CYP Enzymes in Mouse and Human Liver by Pilocarpine. Br. J. Pharmacol. 1995, 114, 832-836.
28. Taavitsainen, P.; Juvonen, R.; Pelkonen, O. In Vitro Inhibition of Cytochrome P450 Enzymes in Human Liver Microsomes by a Potent CYP2A6 Inhibitor, Trans-2-phenylcyclopropylamine (tranylcypromine), and its Nonamine Analog, Cyclopropylbenzene. Drug Metab. Dispos. 2001, 29, 217-222.
29. Chang, T. K.H.; Waxman, D. J. The CYP2A Subfamily. In Cytochromes P450 Metabolic and Toxicological Aspects; Ionnides, C., Ed.; CRC Press: Boca Raton, 1996; pp 99-134.
30. Pelkonen, O.; Raunio, H.; Rautio, A.; Pasanen, M.; Lang, M. A. The Metabolism of Coumarin. In Coumarins: Biology, Applications and Mode of Action; O'Kennedy, R., Thornes, R. D., Eds.; John Wiley & Sons Ltd: Chichester; New York 1997; pp 67-92.
31. Pelkonen, O.; Rautio, A.; Raunio, H.; Pasanen, M. CYP2A6: a Human Coumarin 7-Hydroxylase. Toxicology 2000, 144, 139-147.
32. Aitio, A. A Simple and Sensitive Assay of 7-Ethoxycoumarin Deethylation. Anal. Biochem. 1978, 85, 488-491.
33. Rahnasto, M.; Raunio, H.; Poso, A.; Juvonen, R. O. More Potent Inhibition of Human CYP2A6 than Mouse CYP2A5 Enzyme Activities by Derivatives of Phenylethylamine and Benzaldehyde. Xenobiotica 2003, 33, 529-539.
34. m. Anal. Biochem. 1994, 221, 53-56.
35. Venalainen, J. I.; Juvonen, R. O.; Forsberg, G. M. M.; Garcia-Horsman, A.; Poso, A.; Wallen, E. A.; Gynther, J.; Mannisto, P. T. Substrate-Dependent, Non-Hyperbolic Kinetics of Pig Brain Prolyl Oligopeptidase and its Tight Binding Inhibition by JTP-4819. Biochem. Pharmacol. 2002, 64, 463-471.
36. Cramer, R. D.; Patterson, D. E., III; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
37. Clark, M.; Cramer, R. D. I.; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
38. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: a New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1993, 115, 8.
39. Miles, J. S.; Mclaren, A. W.; Forrester, L. M.; Glancey, M. J.; Lang, M. A.; Wolf, C. R. Identification of the Human Liver Cytochrome P-450 Responsible for Coumarin 7-Hydroxylase Activity. Biochem. J. 1990, 267, 365-371.
40. Yamano, S.; Tatsuno, J.; Gonzales, F. J. The CYP2A3 Gene Product Catalyzes Coumarin 7-Hydroxylation in Human Liver Microsomes. Biochemistry 1990, 29, 1322-1329.
41. Coh Substrate Specificity by Mutation of a Single Amino-Acid Residue. Nature 1989, 339, 632-634.
42. Lewis, D. F.; Lake, B. G. Species Differences in Coumarin Metabolism: a Molecular Modelling Evaluation of CYP2A Interactions. Xenobiotica 2002, 32, 547-561.
43. Lewis, D. F. V.; Dickins, M. Substrate SARs in Human P450s. Drug Discovery Today 2002, 7, 918-925.
44. Lewis, D. F. V. Essential Requirements for Substrate Binding Affinity and Selectivity Toward Human CYP2 Family Enzymes. Arch. Biochem. Biophys. 2003, 409, 32-44.
45. Lewis, D. F. V.; Modi, S.; Dickins, M. Structure-Activity Relationship for Human Cytochrome P450 Substrates and Inhibitors. Drug Metab. Rev. 2002, 34, 69-82.
46. Lewis, D. F. V.; Gorrod, J. W. Molecular Orbital Calculations and Nicotine Metabolism: a Rationale for Experimentally Observes Metabolite Ratios. Drug Metab. Drug Interact. 2002, 19, 29-39.